VIRUN secures $2.1 million in funding

VIRUN secures $2.1 million in funding

Encapsulation company is set to expand its portfolio with money from Bluestem and private investors.

After almost 10 years of self-funding growth and business expansion, VIRUN is ready to further illuminate its presence and capitalize on its patented technology portfolio and product development.

VIRUN has successfully raised $2.1 million from Bluestem, a Midwest private equity firm, in addition to private investors. The financing closed mid-July following the successful obtainment of several notices of allowances and patent grants for key technologies in the area of food, beverage, consumer products and pharmaceuticals.

In the beginning
VIRUN was founded in 2003 as a biopharmaceutical corporation improving the pharmacokinetics and dynamics of drugs through its patented oral transferrin bound delivery technologies (MAPT). In 2004, VIRUN achieved greater than 61 percent oral bioavailability of human insulin compared to intravenous injection. One of the outcomes of VIRUN’s pharmaceutical innovations was the development of encapsulation technologies that allowed increase absorption of non-polar (oil-soluble active constituent) compounds called “compositions.” These compositions were applied to VIRUN’s MAPT but also researched for toxicology and safety. An unexpected outcome was that the encapsulation technologies showed that the ingredients used to make the composition (emulsifier) did not significantly absorb into blood serum, yet, the non-polar active constituent did. This, among other things, gave birth to a new patented delivery of non-polar active constituents, such as omega-3 EPA and DHA, into foods and beverages now branded OmegaH2O®. The Omega-3 EPA and DHA dissolves clear into beverages, with no impact on odor or taste, and is shelf stable. Even more importantly, the resultant formulation is safe since only the omega-3 significantly absorbs in the body. There is no need for EDTA or preservatives, there are no detergents or polysorbates.

Strengthening through partnering
VIRUN’s success can be attributed to its ability to partner and joint venture with a range of companies seeking differentiation in the health, energy and diet foods and beverages markets. Our broad based partnerships range from fortune 100-plus companies to small development businesses looking to gain a competitive-edge in a crowded industry. Bluestem’s partnership with VIRUN comes as no surprise. Its management team, business portfolio and track record have provided high returns for its investors over many years and several funds. VIRUN can benefit, not just from the financial injection, but also with Bluestem as an active board member adding key decision-making helping support VIRUN’s continued growth. Our partners for handling intellectual property matters, litigation and trademarks, McKenna Long & Aldridge LLP, recognize the continued interest from industry and their meticulousness is commendable. The law firm of Nevers, Palazzo, Packard, Wildermuth & Wynner, Virun’s legal counsel on the transaction, will continue to assist VIRUN’s ascendancy. Partnering is an important aspect, benevolence essential.

Philip Bromley, CEO of VIRUN, stated, "We don’t see Bluestem as a ‘venture capital’ company, rather, a partner and mentor; VIRUN’s three segments of business, food/beverage, consumer products and pharmaceutical development, are our solid foundation for rapid growth.” Mr. Bromley further stated, “VIRUN will continue our mutual and ethical mode-of-thinking and share its success with those who wish to share and succeed with us. Thank you for your continued support.”

Tyler Stowater, vice president/partner at Bluestem and VIRUN director stated, "Bluestem believes in partnering with companies that secure long-term, sustainable growth manifesting strong returns to shareholders. VIRUN is a diamond-in-the-ruff, partnering with them further emphasizes our goal to assist growing companies and create revenue driven success – as VIRUN delivers ‘clear solutions,’ Bluestem delivers the design at which to actuate.’”

Rick Crandall, VIRUN director, stated, “My experience and involvement in successful business development will focus on helping the management team take the Company to the next level of growth and profitability. VIRUN has clearly innovated within a vibrant industry that has been searching for ways to create health and energy beverages with great taste and last on store shelves without being refrigerated. This is a game changer in the specialty drinks market.”

What is next
So far, VIRUN has developed the only shelf-stable and clear omega-3 EPA and DHA that is currently on the market. The same technology is being applied with the same results using CO Q10, vitamin D3, resveratrol and other well-accepted health ingredients. In addition, VIRUN has created a drug delivery platform utilizing natural transferrin technology to deliver drugs orally and with improved effectiveness. Consumer products are in development with major food, beverage and pharmaceutical companies world-wide.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.